← Back
Compass Therapeutics
CMPX · listed on Nasdaq · worth $141.64 million
$0.7714
+1.33% on Nov 4
Two insider buys in the last year, $21.3K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
132.4M shares
74% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider bought Compass Therapeutics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Chief Accounting Officer
Neil Lerner
Bought $18.4K on Oct 1 — 20,000 shares at $0.9200, 4.8% of what they now own.
No earlier purchases to measure
Big investors
People and funds that reported owning 5% or more of Compass Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.State Street5.5%Aug 7
All reports
Every insider trade and SEC report we hold for Compass Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Analysts, earnings and news
Analysts' price target
$5.50 average
12 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 4 quarters above
Q2 '26−$0.13 a share−$0.02
Q1 '26−$0.10 a share+$0.00
Q4 '25−$0.09 a share−$0.00
Q3 '25−$0.08 a share+$0.05